Alpha(1)-acid glycoprotein is contained in bovine neutrophil granules and released after activation.
The present study was designed to investigate the capability of bovine neutrophil granulocytes to produce the minor acute phase protein alpha(1)-acid glycoprotein (AGP, Orososmucoid). Bovine neutrophils contain a high MW (50-60kDa) AGP isoform (PMN-AGP), as determined by Western blotting and confirmed by fluorescence microscopy. The presence of AGP in bovine neutrophils has been confirmed by fluorescence immunocytometry. In addition, bovine neutrophils contain also a 42-45kDa isoform, which has the same MW as plasma-, liver-delivered, AGP. cDNA sequence of plasma- and PMN-AGP revealed that (i) the two proteins are products of the same gene; (ii) the differences in molecular weight are due do different post-translational modifications. This result was confirmed by deglycosylation of the two glycoforms. Exocytosis studies showed that isolated neutrophils exposed to several challengers, including Zymosan activated serum (ZAS) and phorbol 12-myristate 13-acetate (PMA), which mimic the inflammatory activation, released PMN-AGP as early as 15min. AGP's mRNA is physiologically expressed by mature resting neutrophils. Real-time PCR on LPS, ZAS and PMA challenged cells revealed that the level of expression apparently does not increase after inflammatory activation. Collectively, the findings reported in this paper proved that PMN-AGP: (i) is a hyperglycosylated glycoform of plasma AGP, (ii) is stored in granules, and (iii) is released by neutrophils in response to activation. Due to its anti-inflammatory activity, PMN-AGP may work as a fine tuning of the neutrophils functions in the inflammatory focus, i.e. it can reduce the damages caused by an excess of inflammatory response.
Rahman
Mizanur M D
MM
Department of Animal Pathology, Hygiene and Veterinary Public Health, University of Milano, Via Celoria 10, 20133 Milano, Italy.
Miranda-Ribera
Alba
A
Lecchi
Cristina
C
Bronzo
Valerio
V
Sartorelli
Paola
P
Franciosi
Federica
F
Ceciliani
Fabrizio
F
D000818:Animals; D002417:Cattle / Q000097:blood / Q000276:immunology*; D005089:Exocytosis / Q000276:immunology; D005260:Female; D008070:Lipopolysaccharides / Q000494:pharmacology; D018375:Neutrophil Activation / Q000187:drug effects / Q000276:immunology*; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D009961:Orosomucoid / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology*; D020033:Protein Isoforms; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000662:veterinary; D018709:Statistics, Nonparametric; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D015054:Zymosan / Q000494:pharmacology
D008070:Lipopolysaccharides; D009961:Orosomucoid; D020033:Protein Isoforms; D012333:RNA, Messenger; D015054:Zymosan; D013755:Tetradecanoylphorbol Acetate